The company statement went on to underline that InvaGen Pharmaceuticals is not linked directly to the flagship companies of the Hetero group i.e. Hetero Drugs or Hetero Labs
The Hetero group has clarified that the current sale of InvaGen Pharmaceuticals to Cipla is the sale of a strategic investment by the Hetero promoter group which has a different product portfolio from Hetero Drugs or Hetero Labs. (See Express Pharma news:(http://www.expressbpd.com/article/pharma/latest-updates/cipla-to-acquire-us-based-invagen-pharmaceuticals-and-exelan-pharmaceuticals/130303/)
The company statement went on to underline that InvaGen Pharmaceuticals is not linked directly to the flagship companies of the Hetero group i.e. Hetero Drugs or Hetero Labs.
Hetero has currently 130 ANDAs filed in US and according to the company statement, it will continue to strengthen its presence in the US market by investing in US generics and speciality products through its subsidiary firm Camber Pharmaceuticals Inc in US. The company statement was issued to clarify reports on Hetero’s US business carried by some business dailies and news channels.
Comments are closed.